

Muscles affected: _____



CLOSTRIDIUM BOTULINUM TYPE A TOXIN

Modified Ashworth Score	<input type="text"/>
-------------------------	----------------------

Total Dysport® Dose	<input type="text"/>
---------------------	----------------------

ICD Code	<input type="text"/>
Nappi Code	<input type="text"/>

NEW Indication Hemifacial spasm¹

Diagram illustrating the muscles of the face and their corresponding Dysport® Dose input boxes:

- Frontalis²
- Procerus²
- Upper medial orbicularis oculi²
- Upper lateral orbicularis oculi²
- Lower lateral orbicularis oculi²
- Lower medial orbicularis oculi²
- Zygomaticus²
- Buccinator²
- Orbicularis oris²
- Platysma²


Muscles affected: _____

Modified Ashworth Score	
-------------------------	--

Total Dysport® Dose	
---------------------	--

ICD Code	
Nappi Code	

NEW Indication Blepharospasm¹



References: 1. Dysport Professional Information. March 2022. 2. Agur AMR, Dalley AF. Grant's Atlas of Anatomy Edition 15. Wolters Kluwer, 2021;606-611.

[S4] Dysport® Each vial contains 500 U of *Clostridium botulinum* type A toxin-haemagglutinin complex. Excipients: Human albumin solution, lactose monohydrate. Reg No.: 37/30.4/0683. HCR: Acino Pharma (Pty) Ltd. Reg. No.:1994/008717/07. 106, 16th Road, Midrand,1686. AP012 24/01/2024 Exp: 24/01/2026